Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media?

Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media?
复制标题

DOI:
10.1007/s00330-009-1698-6
复制
发表时间:
2010-07-01
期刊:
影响因子:
5.9
通讯作者:
Kohda, Ehiichi
Kohda, Ehiichi
中科院分区:
医学2区
文献类型:
--
作者:
Gomi, Tatsuya;Nagamoto, Masashi;Kohda, Ehiichi

文献摘要

被引文献

相似文献

不同低渗透压非离子造影剂中不良反应的差异此前未见研究。因此,本研究的目的是确定五种不同的低渗透压非离子造影剂中不良反应发生率的差异。我们前瞻性地记录了8,931例连续CT患者使用的五种不同的低渗透性非离子造影剂相关的所有不良事件。患者被随机分为五组:iomeprol 300 mgI/ml、iopamidol 300 mgI/ml、iohexol 300 mgI/ml、ioproide 300 mgI/ml和ioversol 320 mgI/ml。241例(2.7%)患者出现不良事件。急性不良反应发生率在以下组中显著升高:(1)iomeprol组(3.9%)和ioproide组(3.5%),(2)59岁及以下患者(4.5%)比60岁及以上患者(1.9%),(3)首次使用造影剂组(3.5%)比晚期使用造影剂组(2.3%),(4)有造影剂不良反应史的患者(11.2%),(5)首次使用造影剂组(3.3%)比既往使用过造影剂组(2.0%)。年轻患者使用iopamidol、iohexol和ioversol可降低急性不良反应的发生率。
The differences regarding adverse reactions in different low-osmolar non-ionic contrast media had not been investigated previously. Thus, the aims of this study were to identify differences in the incidence of adverse reactions in five different low-osmolar non-ionic contrast media.We prospectively recorded all adverse events associated with five different low-osmolar non-ionic contrast media used in 8,931 consecutive patients for CT. Patients were randomly assigned to five groups: iomeprol 300 mgI/ml, iopamidol 300 mgI/ml, iohexol 300 mgI/ml, iopromide 300 mgI/ml and ioversol 320 mgI/ml.Adverse events were observed in 241 patients (2.7%). The incidence of acute adverse reactions was significantly higher in the following groups: (1) iomeprol (3.9%) and iopromide (3.5%) groups, (2) patients aged 59 years or less (4.5%) compared with those aged 60 years or over (1.9%), (3) the first period (3.5%) compared with the late period (2.3%), (4) those with a past history of adverse reactions to contrast media (11.2%), and (5) patients receiving contrast media for the first time (3.3%) compared with those had received it previously (2.0%).The incidence of acute adverse reactions may be reduced in younger patients by using iopamidol, iohexol and ioversol.